Select             pdf
Trial Studied trt Control trt patientstagsROB Trial resultdeath (overall survival) progression or death (progression free survival PFS)

renal-cell carcinoma (advanced)  

METEOR, 2015    NCTcabozantinibeverolimus after VEGFR-targeted therapy failure 2nd line Risk of bias suggesting-33%-42%
CABOSUN, 2017      NCTcabozantinibsunitinibfirst-line therapy in patients with intermediate- or poor-risk 1st line Exploratory suggesting-34%